Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016

References

• Falk RH, Alexander KM, Liao R, et al. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016;68:1323–1341.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Buadi FK, Dispenzieri A, et al. Immunoglobulin light chain amyloidosis from basics to new developments in diagnosis, prognosis and therapy. Acta Haematol. 2016;135:172–190.
   PubMed Web of Science ®Google Scholar
• Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood. 2016;128:159–168.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. JCO. 2004;22:3751–3757.
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. JCO. 2012;30:989–995.
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26:2317–2325.
   PubMed Web of Science ®Google Scholar
• Weber N, Mollee P, Augustson B, et al. Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Intern Med J. 2015;45:371–382.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641–2654.
   PubMed Web of Science ®Google Scholar
• Hazenberg B, Croockewit A, Holt B, et al. Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase ii HOVON-41 study by the Dutch-Belgian co-operative trial group for hematology oncology. Haematologica. 2015;100:677–682.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol. 2016;91:947–956.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Gertz MA, Kumar SK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129:2111–2119.
   PubMed Web of Science ®Google Scholar
• Janssen S, Van Rijswijk MH, Meijer S, et al. Systemic amyloidosis: a clinical survey of 144 cases. Neth J Med. 1986;29:376–385.
   PubMed Web of Science ®Google Scholar
• Hazenberg B, van Rijswijk MH, Lub-de Hooge MN, et al. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis. J Nucl Med. 2007;48:865–872.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol. 2005;79:319–328.
   PubMed Web of Science ®Google Scholar
• Lousada I, Comenzo R, Landau H, et al. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther. 2015;32:920–928.
   PubMed Web of Science ®Google Scholar
• Palladini G, Kyle RA, Larson DR, et al. Multicentre versus single centre approach to rare diseases the model of systemic light chain amyloidosis. Amyloid. 2005;12:120–126.
   PubMed Web of Science ®Google Scholar
• Huang XH, Liu ZH. The clinical presentation and management of systemic light chain amyloidosis in China. Kidney Dis. 2016;2:1–9.
   Google Scholar
• Sanchorawala V, Wright DG, Seldin DC, et al. High-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant. 2004;33:381–388.
   PubMed Web of Science ®Google Scholar
• Hemminki K, Li X, Försti A, et al. Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health. 2012;12:974.
   PubMed Web of Science ®Google Scholar
• D'Souza A, Dispenzieri A, Wirk B, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a center for international blood and marrow transplant research study. JCO. 2015;33:3741–3749.
   PubMed Web of Science ®Google Scholar